Is ChemoCentryx, Inc. (CCXI) a Buy? The Stock Rises Again

March 14, 2018 - By Henry Gaston

Investors sentiment decreased to 1.14 in 2017 Q3. Its down 0.26, from 1.4 in 2017Q2. It fall, as 12 investors sold ChemoCentryx, Inc. shares while 23 reduced holdings. 12 funds opened positions while 28 raised stakes. 23.75 million shares or 2.21% less from 24.29 million shares in 2017Q2 were reported.
Amer Interest reported 16,364 shares. Schwab Charles Investment Mgmt owns 35,200 shares for 0% of their portfolio. Nationwide Fund Advisors, Pennsylvania-based fund reported 13,828 shares. Citigroup has 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 1,843 shares. State Of Wisconsin Board has invested 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Artal Gp reported 0.06% in ChemoCentryx, Inc. (NASDAQ:CCXI). California State Teachers Retirement stated it has 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Proshare Advsrs Llc holds 0% or 29,111 shares. Baker Bros Advsr L P invested in 0% or 49,064 shares. Citadel Advsrs Ltd Liability Company stated it has 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Jacobs Levy Equity Incorporated holds 0.02% or 119,721 shares in its portfolio. Sio Capital Management Ltd Liability stated it has 0.1% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Keybank Natl Association Oh, Ohio-based fund reported 40,438 shares. Federated Invsts Pa has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Royal State Bank Of Canada invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI).

The stock of ChemoCentryx, Inc. (NASDAQ:CCXI) is a huge mover today! The stock increased 10.56% or $1.35 during the last trading session, reaching $14.14. About 779,023 shares traded or 195.78% up from the average. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 60.64% since March 14, 2017 and is uptrending. It has outperformed by 43.94% the S&P500.
The move comes after 7 months positive chart setup for the $689.56 million company. It was reported on Mar, 14 by We have $15.13 PT which if reached, will make NASDAQ:CCXI worth $48.27M more.

Analysts await ChemoCentryx, Inc. (NASDAQ:CCXI) to report earnings on May, 9. They expect $-0.19 earnings per share, down 58.33 % or $0.07 from last year’s $-0.12 per share. After $0.80 actual earnings per share reported by ChemoCentryx, Inc. for the previous quarter, Wall Street now forecasts -123.75 % negative EPS growth.

ChemoCentryx, Inc. (NASDAQ:CCXI) Ratings Coverage

Among 4 analysts covering ChemoCentryx (NASDAQ:CCXI), 2 have Buy rating, 1 Sell and 1 Hold. Therefore 50% are positive. ChemoCentryx had 6 analyst reports since September 3, 2015 according to SRatingsIntel. The rating was maintained by Cowen & Co with “Hold” on Tuesday, August 8. The firm earned “Buy” rating on Thursday, August 10 by JMP Securities. The stock of ChemoCentryx, Inc. (NASDAQ:CCXI) has “Sell” rating given on Monday, September 21 by Zacks. The company was initiated on Tuesday, February 21 by JMP Securities. On Thursday, September 3 the stock rating was downgraded by Zacks to “Sell”. The company was maintained on Tuesday, March 13 by JP Morgan.

More news for ChemoCentryx, Inc. (NASDAQ:CCXI) were recently published by:, which released: “ChemoCentryx Reports Fourth Quarter and Full Year 2017 Financial Results and …” on March 09, 2018.‘s article titled: “ChemoCentryx Inc (CCXI) Files 10-K for the Fiscal Year Ended on December 31, 2017” and published on March 13, 2018 is yet another important article.

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company has market cap of $689.56 million. The Company’s lead drug candidate is Avacopan , an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor (C5Ar), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). It has a 39.28 P/E ratio. The firm also engages in developing CCX140, an inhibitor of the chemokine receptor known as CCR2 for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease; Vercirnon for the treatment of patients with moderate-to-severe CrohnÂ’s diseases; CCX872, a selective inhibitor of the human CCR2 that has completed Phase I clinical trial for the treatment of pancreatic cancer; CCX507, which has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th17 cells for the treatment of psoriasis, rheumatoid arthritis, asthma, and multiple sclerosis.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.